Sponsorship verdict
Sponsorship possible
One solid signal, not two. Worth applying, and worth asking about sponsorship early.
-
✓
Employer is on a government sponsor recordThe US Department of Labor certified 1 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Mar 2026) — the step every H-1B hire needs first.
-
?
The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
-
?
No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area.
-
✓
Confirmed live todayWhen a source last listed this job as open.
Details and sources
- Employer is on a government sponsor record
- The US Department of Labor certified 1 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Mar 2026) — the step every H-1B hire needs first. Source: LCA disclosure data (US Department of Labor (OFLC)).
- No salary bar for this route
- H-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence. It is not legal advice and never a guarantee: the employer and the immigration authority decide. Sign in to factor in where you can already work.
About the role
About Stoke:
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke’s proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit https://www.stoketherapeutics.com/
Position Purpose
Reporting directly to the Chief Financial Officer, the Senior Vice President, Accounting and Corporate Controller is the enterprise owner of Stoke’s accounting operations, external financial reporting, corporate tax, and internal control environment. As Stoke moves from a pre-commercial to a commercial-stage organization, this leader will architect and execute the build-out of a scalable, audit-ready finance infrastructure that supports commercial revenue, an expanding clinical pipeline, and the disclosure standards expected of a public company.
This role is trusted advisor to the CFO, executive leadership team, Audit Committee, and external auditors. The successful candidate will bring a record of SEC reporting excellence, SOX leadership, and technical accounting depth in life sciences, along with the judgment and credibility to shape financial strategy as well as execute it.
Key Responsibilities
Enterprise Accounting Leadership
• Lead all global accounting operations, including general ledger, accounts payable, payroll, inventory, and cost accounting, and ensure the function is designed to support commercial-scale operations
• Establish the operating model, governance, and performance standards for a best-in-class close process, driving accuracy, speed, and consistency
SEC Reporting & Public Company Compliance
• Own the integrity, timeliness, and quality of all SEC filings, including Forms 10-K, 10-Q, and 8-K, and ensure full compliance with US GAAP and SEC regulations
• Partner with the CFO, Legal, and Investor Relations on disclosure controls, earnings materials, and Audit Committee reporting
Technical Accounting & Commercial Revenue Recognition
• Serve as the Company’s senior technical accounting authority, setting policy and positions on complex transactions including gross-to-net (GTN) revenue deductions, distributor agreements, and collaborative R&D arrangements
• Anticipate the accounting implications of commercial launch, partnerships, and business development activity, and advise leadership before decisions are made
Internal Controls & SOX Compliance
• Maintain, test, and continuously strengthen the internal control framework in compliance with SOX Section 404, proactively managing risk as commercial operations expand
• Drive standardization, automation, and systems enhancements that improve control effectiveness and operating efficiency
Inventory & Supply Chain Accounting
• Direct the accounting framework for clinical and commercial inventory, including capitalization, allocation, and valuation, and for financial oversight of third-party logistics (3PL) partners
Tax & Treasury Partnership
• Oversee external advisors in the delivery of corporate tax compliance, ASC 740 income tax accounting, and R&D tax credit strategy
• S
Apply on employer site ↗